12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral anti-neoplastic drugs cancer data

Researchers at Medco Health conducted a retrospective analysis of its pharmacy claims database showing that 23-74% of about 11,600 patients who were prescribed 1 of 9 oral OADs between January 2008 and May 2010 were also receiving a drug that had the potential to reduce effectiveness or increase toxicity of the OAD. Specifically, 43% of patients who received imatinib in the analysis (n=4,617) were also prescribed a drug that could impair the cancer drug's efficacy, while 68% also received a drug that could...

Read the full 395 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >